SCHEMBL447510

SCHEMBL447510

Cc1ncc2c(c1O)COC2

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.61
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
CYP1A2 P05177 1/20 0.61
CYP2D6 P10635 1/20 0.61
CYP2C19 P33261 1/20 0.61
P2RX3 P56373 1/20 0.61
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 1/20 0.35
PRKCG P05129 1/20 0.34
PRKCA P17252 1/20 0.34
PRKCD Q05655 1/20 0.34
MAPT P10636 1/20 0.33
LMNA P02545 2/20 0.33
PDXK O00764 1/20 0.32
AOX1 Q06278 1/20 0.32
TRIM24 O15164 1/20 0.31
TRIM33 Q9UPN9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11161014 0.98 KDM4E (0.59) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL4466115 0.93 KDM4E (0.58) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL4459404 0.79 KMT2A (0.51) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL22019794 0.74 KDM4E (0.36) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL10376243 0.73 KDM4E (0.36) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL10821596 0.73 PDXK (0.38) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL23857473 0.70 PDE4D (0.40) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL12673717 0.69 KMT2A (0.39) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL10732292 0.69 KDM4E (0.42) KDM4EKMT2AMEN1CYP1A2CYP2D6
SCHEMBL13107698 0.69 KDM4E (0.42) KDM4EKMT2AMEN1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028470-A1 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2011-02-03 US claimed
US-7645882-B2 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-01-12 US claimed
US-20070123577-A1 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2007-05-31 US claimed
EP-1693369-A1 PROTEIN MODIFIER PRODUCTION INHIBITOR TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2006-08-23 EP claimed
EP-1398316-B1 Process for the preparation of 1,3-Dihydro-6-methylfuro(3,4-c)pyridin-7-ol Derivatives GENERICS UK LTD (GB) 2006-06-14 EP claimed
WO-2005090356-A1 1,3 DIHYDROFURO [3,4-c]PYRIDINES AND THEIR PREPARATION DSM IP ASSETS B.V. (NL) 2005-09-29 WO claimed
EP-1398316-A2 Process for the preparation of 1,3-Dihydro-6-methylfuro(3,4-c)pyridin-7-ol Derivatives Generics (UK) Limited (GB) 2004-03-17 EP claimed
US-4735950-A DIURETICS, HYPOTENSIVE AGENT, ANTILIPEMIC AGENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) 1988-04-05 US claimed
US-4585776-A DIURETIC HYPOTENSIVE SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1986-04-29 US claimed
US-4581363-A DIURETICS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1986-04-08 US claimed
EP-0035716-B1 4-ALPHA-CYCLOAMINOARYLMETHYL-6-METHYL-1,3-DIHYDRO FURO (3,4-C)PYRIDIN-7-OLS, THEIR PREPARATION AND USE BASF Aktiengesellschaft (DE) 1983-06-29 EP claimed
US-4383998-A Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 1983-05-17 US claimed
EP-0035716-A1 4-Alpha-cycloaminoarylmethyl-6-methyl-1,3-dihydro furo (3,4-c)pyridin-7-ols, their preparation and use BASF Aktiengesellschaft (DE) 1981-09-16 EP claimed
US-20140335517-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA RENASCIENCE CO LTD (JP) 2014-11-13 US disclosed
US-8809329-B2 Detection and treatment of schizophrenia TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) 2014-08-19 US disclosed
EP-2662453-A2 Detection and treatment of schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2013-11-13 EP disclosed
US-4383998-A Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 1983-05-17 US disclosed
US-4383998-A Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) 1983-05-17 US disclosed
US-4335241-A INTERMEDIATES FOR ANTIARRHYTHMIA AGENTS BASF AKTIENGESELLSCHAFT (DE) 1982-06-15 US disclosed
EP-0035716-A1 4-Alpha-cycloaminoarylmethyl-6-methyl-1,3-dihydro furo (3,4-c)pyridin-7-ols, their preparation and use BASF Aktiengesellschaft (DE) 1981-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123577-A1 Inhibitor of protein modification products formation SERPINB6, PROC, PLPBP KDM4E 2177/4885KMT2A 2334/4885MEN1 1277/4885
US-20110028470-A1 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 KDM4E 1357/4885KMT2A 1703/4885MEN1 4818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.